Deals· July 30, 2026 · 21 min read
Biogen's $5.6B Apellis Acquisition: Syfovre & Empaveli Q2 2026 Financial Deep Dive
By Ran Chen#M&A#Commercial Strategy#Ophthalmology
Topic
Commercial Strategy
Launch planning, revenue forecasting, commercial operations, and strategic decision-making for biopharma products.
Deals· July 20, 2026 · 17 min read
2026 biopharma M&A by the numbers: 33 deals and $134 billion already eclipse all of 2025
By Ran Chen#M&A#Oncology#Immunology
People· July 17, 2026 · 18 min read
CMS Open Payments 2025: $3.92B General and $9.50B Research by the Numbers
By Ran Chen#Drug Pricing#Commercial Strategy#Regulatory
Policy· June 30, 2026 · 18 min read
China's 2026 Medical Representative Measures: Building a Compliant Model
By Ran Chen#China#NMPA#Market Access
Biosimilars· June 1, 2026 · 12 min read
FDA biosimilar interchangeability without switching studies: the 2026 pathway
By Ran Chen#Biosimilars#Interchangeability#FDA Approval
Policy· May 22, 2026 · 11 min read
Labeling supplement timing after a new indication approval and why launch teams miss it
Policy· May 22, 2026 · 10 min read